IL2RB and neoplasm: Compared to cells with orthogonal IL-2Rβ, cells with the orthogonal chimeric receptor for IL-9 signals demonstrated superior anti-tumor efficacy in two challenging syngeneic mouse solid tumor models of melanoma and pancreatic cancer, even in the absence of lymphodepletion conditioning.